Analysis of pathological classification of 3 071 case of gastric cancer in China
Received date: 2022-10-20
Online published: 2023-01-29
目的:探讨中国胃癌的病理分型特点。方法:选取2019年1月至2022年7月在上海交通大学医学院附属瑞金医院进行连续手术的3 071例胃癌病例,根据2019年第5版世界卫生组织(World Health Organization,WHO)消化系统肿瘤新分类中的胃癌分型,分析其临床和病理特点。结果:3 071例胃癌患者中有3 003例患者经病理诊断为胃腺癌(97.79%)。胃腺癌的男女发病比为2.18:1,患者中位年龄为64岁。本研究中,管状腺癌、乳头状腺癌、混合型腺癌、低黏附性癌和黏液腺癌是常见的组织学亚型,这5种组织学亚型占所有胃腺癌的构成比为99.03%。982例胃癌标本进行了Lauren分型的患者中,肠型腺癌相对多见,构成比为46.03%,与弥漫型腺癌病例数之比为1.39:1。在3 003例胃腺癌病例中,有172例(5.73%)存在错配修复蛋白表达缺失(mismatch repair deficiency, dMMR),而其中163例(94.77%)为MLH1/PMS2型缺失。3 003例胃腺癌患者中,EB病毒编码小RNA(Epstein-Barr encoded RNA,EBER)阳性率为1.40%(42/3 003)。3 003例胃腺癌样本中,661例人表皮生长因子受体2(human epidermal growth factor receptor-2, HER2)蛋白表达结果为1+,而2+及3+的例数分别为229例和113例。结论:中国人胃癌病理亚型分布有其独特特征,肠型腺癌与弥漫型腺癌的比率低于亚洲平均水平;EB病毒阳性型胃癌占比低于国内外平均水平;HER2免疫组化检测结果为2+及以上病例数所占比例也低于国外报道。
马乾宸, 张本炎, 芮炜玮, 王婷, 罗方秀, 王朝夫, 袁菲 . 中国3 071例胃癌病理分型分析[J]. 诊断学理论与实践, 2022 , 21(05) : 560 -566 . DOI: 10.16150/j.1671-2870.2022.05.003
Objective: To retrospectively analyze the clinicopathological data of gastric cancer (GC) in order to investigate the histological classification and epidemiological characteristics of GC in China. Methods: A total of 3 071 cases of malignant gastric epithelial tumors who underwent surgery in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from January 2019 to July 2022 were included. The relevant pathological and clinical data were summarized and analyzed according to the 5th Edition of WHO classification of digestive system tumors and literatures was reviewed. Results: Among 3 071 cases of GC, 3 003 were diagnosed as having adenocarcinoma. The male to female incidence ratio was 2.18:1, with a median age of 64 years. It showed tubular adenocarcinoma, papillary adenocarcinoma, mixed adenocarcinoma, poorly cohesive carcinoma and mucinous adenocarcinoma are the most common. In this study, these 5 histological subtypes accounted for 96.84% of all gastric adenocarcinomas. For Lauren classification, ratio of intestinal type to diffuse type was 1.39:1. MMR deficiency was found in 5.73% of gastric adenocarcinoma cases, among which 163 cases were with loss of MLH1 and PMS2 expression. It revealed that 1.40% of the cases were positive for Epstein-Barr virus encoded small RNA (EBER). In the human epidermal growth factor receptor-2 (HER2) testing by immunohistochemistry (IHC) for adenocarcinoma, the cases of protein expression for IHC score 2+ and 3+ were 229 and 113. Conclusions: The pathological subtype distribution of gastric cancer in China has its unique characteristics, with a ratio of intestinal adenocarcinoma to diffuse adenocarcinoma lower than average level in Asian. The proportion of Epstein-Barr virus (EBV) positive gastric cancer is lower than the average level at abroad, while the proportions of cases with HER2 IHC score 2+ or 3+ are also lower than foreign reports.
[1] | Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2019, 5(12):1749-1768. |
[2] | Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J/OL]. Gastric Cancer, 2020-02-14[2022-10-20]. https://link.springer.com/article/10.1007/s10120-020-01042-y. |
[3] | Eom DW, Kang GH, Han SH, et al. Gastric micropapillary carcinoma: a distinct subtype with a significantly worse prognosis in TNM stages Ⅰ and Ⅱ[J]. Am J Surg Pathol, 2011, 35(1):84-91. |
[4] | Di Pinto F, Armentano R, Arborea G, et al. Are immunohistochemical markers useful in phenotypic gastric cancer classification?[J]. Oncology, 2020, 98(8):566-574. |
[5] | 《胃癌HER2检测指南》编写组. 胃癌HER2检测指南[J]. 中华病理学杂志, 2011, 40(8):553-557. |
[5] | Preparation group of Guidelines for HER2 Detection of Gastric Cancer. Guidelines for HER2 detection in gastric cancer[J]. Chin J Pathol, 2011, 40(8):553-557. |
[6] | The WHO Classification of Tumors Editorial Board. WHO classification of tumours of digestive system tumors[M]. 5th ed. Lyon: IARC press, 2019. |
[7] | Ilic M, Ilic I. Epidemiology of stomach cancer[J]. World J Gastroenterol, 2022, 28(12):1187-1203. |
[8] | 王静雷, 杨一兵, 耿云霞, 等. 1990-2017年中国胃癌发病、患病及死亡状况趋势分析[J]. 中国慢性病预防与控制, 2020, 28(5):321-325. |
[8] | Wang JL, Yang YB, Geng YX, et al. Trend analysis of the morbidity, prevalence and mortality of stomach cancer in China from 1990 to 2017[J]. Chin J Prev Control Chronic Dis, 2020, 28(5):321-325. |
[9] | 齐长松, 程思远, 沈琳. 中国胃癌患者三线治疗的现状及研究进展[J]. 中华肿瘤杂志, 2020, 42(12):983-988. |
[9] | Qi CS, Cheng SY, Shen L. Current status and research progress of third-line treatment for patients with gastric cancer in China[J]. Chin J Oncol, 2020, 42(12):983-988. |
[10] | Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview[J]. Int J Cancer, 2021, 149(4):778-789. |
[11] | Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. |
[12] | Bencivenga M, Treppiedi E, Dal Cero M, et al. The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours[J]. J Surg Oncol, 2020, 121(7):1084-1089. |
[13] | Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas[J]. Cancer Sci, 2009, 100(4):626-632. |
[14] | Yamazawa S, Ushiku T, Shinozaki-Ushiku A, et al. Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma[J]. Am J Surg Pathol, 2017, 41(7):989-997. |
[15] | Chen YC, Fang WL, Wang RF, et al. Clinicopathological variation of lauren classification in gastric cancer[J]. Pathol Oncol Res, 2016, 22(1):197-202. |
[16] | Kushima R. The updated WHO classification of digestive system tumours-gastric adenocarcinoma and dysplasia[J]. Pathologe, 2022, 43(1):8-15. |
[17] | Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer[J]. Br J Surg, 2018, 105(3):159-167. |
[18] | Cho J, Kang SY, Kim KM. MMR protein immunohistochemistry and microsatellite instability in gastric cancers[J]. Pathology, 2019, 51(1):110-113. |
[19] | Zhang L, Wang Y, Li Z, et al. Clinicopathological features of tumor mutation burden, Epstein-barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer[J]. Diagn Pathol, 2021, 16(1):38. |
[20] | Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma[J]. Am J Pathol, 1992, 140(4):769-774. |
[21] | 刘莹, 臧凤琳, 邱志强, 等. 886例胃腺癌患者错配修复蛋白表达和EB病毒感染状态与其临床病理特征的关系[J]. 中华胃肠外科杂志, 2021, 24(5):440-448. |
[21] | Liu Y, Zang FL, Qiu ZQ, et al. Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients[J]. Chin J Gastrointest Surg, 2021, 24(5):440-448. |
[22] | 《胃癌HER2检测指南(2016版)》专家组. 胃癌HER2检测指南(2016版)[J]. 中华病理学杂志, 2016, 45(8):528-532. |
[22] | Guideline Recommendations for HER2 Detection in Gastric Cancer Group. Guidelines for HER2 detection in gastric cancer(2016)[J]. Chin J Pathol, 2016, 45(8):528-532. |
[23] | Suh YS, Na D, Lee JS, et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal Junction between esophageal and gastric adenocarcinomas[J]. Ann Surg, 2022, 275(4):706-717. |
/
〈 |
|
〉 |